The University of Chicago Header Logo

Connection

Geoffrey Greene to Humans

This is a "connection" page, showing publications Geoffrey Greene has written about Humans.
Connection Strength

0.603
  1. Next-Generation ERa Inhibitors for Endocrine-Resistant ER+ Breast Cancer. Endocrinology. 2019 04 01; 160(4):759-769.
    View in: PubMed
    Score: 0.023
  2. Capture of associated targets on chromatin links long-distance chromatin looping to transcriptional coordination. Nat Commun. 2016 09 16; 7:12893.
    View in: PubMed
    Score: 0.019
  3. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv. 2016 06; 2(6):e1501924.
    View in: PubMed
    Score: 0.019
  4. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016 Feb 02; 5.
    View in: PubMed
    Score: 0.018
  5. In memoriam: Elwood Jensen (1920-2012). Endocr Rev. 2013 Dec; 34(6):761-3.
    View in: PubMed
    Score: 0.016
  6. In memoriam: Elwood Jensen (1920-2012). Endocrinology. 2013 Oct; 154(10):3489-91.
    View in: PubMed
    Score: 0.016
  7. Mapping ERß genomic binding sites reveals unique genomic features and identifies EBF1 as an ERß interactor. PLoS One. 2013; 8(8):e71355.
    View in: PubMed
    Score: 0.015
  8. Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting. J Virol Methods. 2011 May; 173(2):266-70.
    View in: PubMed
    Score: 0.013
  9. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat. 2009 Oct; 117(3):505-15.
    View in: PubMed
    Score: 0.011
  10. NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol. 2008 Apr; 4(4):241-7.
    View in: PubMed
    Score: 0.011
  11. An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008 Jun; 149(6):2970-9.
    View in: PubMed
    Score: 0.011
  12. Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. Steroids. 2008 Jan; 73(1):59-68.
    View in: PubMed
    Score: 0.010
  13. Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat. 2008 Feb; 107(3):359-69.
    View in: PubMed
    Score: 0.010
  14. Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep. 2007 Jun; 8(6):563-8.
    View in: PubMed
    Score: 0.010
  15. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem. 2006 Jun 30; 281(26):17909-19.
    View in: PubMed
    Score: 0.009
  16. Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol. 2005 Dec; 19(12):2930-42.
    View in: PubMed
    Score: 0.009
  17. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell. 2005 May 13; 18(4):413-24.
    View in: PubMed
    Score: 0.009
  18. Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol. 2005; 67:309-33.
    View in: PubMed
    Score: 0.009
  19. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell. 2004 Feb 13; 13(3):317-27.
    View in: PubMed
    Score: 0.008
  20. A structural explanation for ERalpha/ERbeta SERM discrimination. Ernst Schering Res Found Workshop. 2004; (46):33-45.
    View in: PubMed
    Score: 0.008
  21. Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"? Mol Cell. 2003 Apr; 11(4):850-1.
    View in: PubMed
    Score: 0.008
  22. Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer. Cancer Commun (Lond). 2023 05; 43(5):615-619.
    View in: PubMed
    Score: 0.007
  23. In vivo imaging reveals estrogen receptor's hidden personality. Nat Med. 2003 Jan; 9(1):22-3.
    View in: PubMed
    Score: 0.007
  24. Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line. Biophys J. 2022 10 04; 121(19):3651-3662.
    View in: PubMed
    Score: 0.007
  25. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 05 16; 11.
    View in: PubMed
    Score: 0.007
  26. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. 2002 May; 9(5):359-64.
    View in: PubMed
    Score: 0.007
  27. Selective pressure of endocrine therapy activates the integrated stress response through NF?B signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res. 2022 03 09; 24(1):19.
    View in: PubMed
    Score: 0.007
  28. A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Sci Transl Med. 2021 07 21; 13(603).
    View in: PubMed
    Score: 0.007
  29. Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Mol Cancer Res. 2021 09; 19(9):1559-1570.
    View in: PubMed
    Score: 0.007
  30. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54.
    View in: PubMed
    Score: 0.007
  31. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21.
    View in: PubMed
    Score: 0.007
  32. Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Mol Cancer Ther. 2021 01; 20(1):11-25.
    View in: PubMed
    Score: 0.006
  33. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
    View in: PubMed
    Score: 0.006
  34. The NF-?B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res. 2020 07; 18(7):1018-1027.
    View in: PubMed
    Score: 0.006
  35. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019 10 22; 29(4):889-903.e10.
    View in: PubMed
    Score: 0.006
  36. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23; 95(7):927-37.
    View in: PubMed
    Score: 0.006
  37. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
    View in: PubMed
    Score: 0.006
  38. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chem Biol. 2018 12 21; 13(12):3374-3384.
    View in: PubMed
    Score: 0.006
  39. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018 06 18; 9(1):2368.
    View in: PubMed
    Score: 0.005
  40. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018 06; 18(6):377-388.
    View in: PubMed
    Score: 0.005
  41. Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol. 2018 08; 94(2):812-822.
    View in: PubMed
    Score: 0.005
  42. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
    View in: PubMed
    Score: 0.005
  43. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983.
    View in: PubMed
    Score: 0.005
  44. Estrogen receptor (alpha and beta) expression in the excurrent ducts of the adult male rat reproductive tract. J Androl. 1997 Nov-Dec; 18(6):602-11.
    View in: PubMed
    Score: 0.005
  45. Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer. Mol Cancer Res. 2017 10; 15(10):1331-1340.
    View in: PubMed
    Score: 0.005
  46. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017 03; 7(3):277-287.
    View in: PubMed
    Score: 0.005
  47. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996 Oct; 63(1):28-33.
    View in: PubMed
    Score: 0.005
  48. A constructivist perspective on clinical social work practice with ethnically diverse clients. Soc Work. 1996 Mar; 41(2):172-80.
    View in: PubMed
    Score: 0.005
  49. Estrogen receptor accessory proteins: effects on receptor-DNA interactions. Environ Health Perspect. 1995 Oct; 103 Suppl 7:23-8.
    View in: PubMed
    Score: 0.004
  50. Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. Mol Endocrinol. 1995 Jun; 9(6):647-58.
    View in: PubMed
    Score: 0.004
  51. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
    View in: PubMed
    Score: 0.004
  52. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Ann Surg Oncol. 1994 Nov; 1(6):495-503.
    View in: PubMed
    Score: 0.004
  53. The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol. 1994 Oct; 8(10):1407-19.
    View in: PubMed
    Score: 0.004
  54. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor a modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014 Oct; 6(10):1328-46.
    View in: PubMed
    Score: 0.004
  55. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec; 45(12):1439-45.
    View in: PubMed
    Score: 0.004
  56. Immunocytochemical assay for estrogen receptor with monoclonal antibody D753P gamma in routinely processed formaldehyde-fixed breast tissue. Comparison with frozen section assay and with monoclonal antibody H222. Cancer. 1993 Jun 01; 71(11):3541-6.
    View in: PubMed
    Score: 0.004
  57. Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics. PLoS One. 2013; 8(5):e64091.
    View in: PubMed
    Score: 0.004
  58. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499.
    View in: PubMed
    Score: 0.004
  59. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
    View in: PubMed
    Score: 0.004
  60. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013 Jan; 137(2):373-82.
    View in: PubMed
    Score: 0.004
  61. Estrogen and progesterone receptor structure and action in breast cancer cells. Cancer Treat Res. 1992; 61:301-15.
    View in: PubMed
    Score: 0.003
  62. Immunohistochemical localization of progesterone receptor in human decidua of early pregnancy. Hum Reprod. 1992 Jan; 7(1):123-7.
    View in: PubMed
    Score: 0.003
  63. An immunohistochemical evaluation of progesterone receptor in frozen sections, paraffin sections, and cytologic imprints of breast carcinomas. Cancer. 1991 Jan 15; 67(2):455-62.
    View in: PubMed
    Score: 0.003
  64. RAC3 is a pro-migratory co-activator of ERa. Oncogene. 2011 Apr 28; 30(17):1984-94.
    View in: PubMed
    Score: 0.003
  65. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer. 1990 Oct 15; 66(8):1663-70.
    View in: PubMed
    Score: 0.003
  66. Subcellular distribution of estrogen receptor and progesterone receptor with and without specific ligand. Am J Pathol. 1989 Nov; 135(5):857-64.
    View in: PubMed
    Score: 0.003
  67. Immunohistochemical assessment of estrogen and progesterone receptors in stored imprints and cryostat sections of breast carcinomas. Ann Surg. 1989 Aug; 210(2):224-8.
    View in: PubMed
    Score: 0.003
  68. Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor alpha knock-in (ENERKI) mice. Steroids. 2009 Nov; 74(12):913-9.
    View in: PubMed
    Score: 0.003
  69. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer. 2009 Jan 30; 9:43.
    View in: PubMed
    Score: 0.003
  70. Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies. Mol Endocrinol. 1988 Aug; 2(8):714-26.
    View in: PubMed
    Score: 0.003
  71. Progesterone receptor distribution in the human endometrium. Analysis using monoclonal antibodies to the human progesterone receptor. Am J Pathol. 1988 Apr; 131(1):112-24.
    View in: PubMed
    Score: 0.003
  72. Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology. 1988 Mar; 122(3):1165-75.
    View in: PubMed
    Score: 0.003
  73. Estrogen and progesterone receptor measurements with monoclonal antibodies. Int J Biol Markers. 1988 Jan-Mar; 3(1):57-9.
    View in: PubMed
    Score: 0.003
  74. CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol. 2008 Feb; 22(2):263-72.
    View in: PubMed
    Score: 0.003
  75. Elemental isomerism: a boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol. 2007 Jun; 14(6):659-69.
    View in: PubMed
    Score: 0.003
  76. Structural analysis of covalently labeled estrogen receptors by limited proteolysis and monoclonal antibody reactivity. Biochemistry. 1987 Apr 21; 26(8):2364-73.
    View in: PubMed
    Score: 0.002
  77. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem. 2007 Jan 25; 50(2):399-403.
    View in: PubMed
    Score: 0.002
  78. Immunochemical studies of estrogen receptors. Prog Clin Biol Res. 1987; 249:283-305.
    View in: PubMed
    Score: 0.002
  79. Health-related quality of life following a clinical weight loss intervention among overweight and obese adults: intervention and 24 month follow-up effects. Health Qual Life Outcomes. 2006 Jul 17; 4:43.
    View in: PubMed
    Score: 0.002
  80. Estrogen receptor localization in the female genital tract. Am J Pathol. 1986 May; 123(2):280-92.
    View in: PubMed
    Score: 0.002
  81. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986 Mar 07; 231(4742):1150-4.
    View in: PubMed
    Score: 0.002
  82. Structure and dynamics of the estrogen receptor. J Steroid Biochem. 1986 Jan; 24(1):1-7.
    View in: PubMed
    Score: 0.002
  83. Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor. Protein Expr Purif. 2006 Jun; 47(2):348-54.
    View in: PubMed
    Score: 0.002
  84. Monoclonal antibody recognition of multiple forms of estrogen receptor tagged with [125I]methoxy-iodovinyl estradiol in ovarian carcinomas. J Clin Endocrinol Metab. 1985 Sep; 61(3):412-7.
    View in: PubMed
    Score: 0.002
  85. Immunoelectron microscopic localization of estrogen receptor with monoclonal estrophilin antibodies. J Histochem Cytochem. 1985 Sep; 33(9):915-24.
    View in: PubMed
    Score: 0.002
  86. Immunocytochemical identification of estrogen receptor in ovarian carcinomas. Localization with monoclonal estrophilin antibodies compared with biochemical assays. Lab Invest. 1985 Sep; 53(3):349-61.
    View in: PubMed
    Score: 0.002
  87. The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue. J Histochem Cytochem. 1985 Feb; 33(2):87-92.
    View in: PubMed
    Score: 0.002
  88. Maxillary sinus cancer: a study of 33 cases. J Oral Pathol. 1985 Jan; 14(1):27-36.
    View in: PubMed
    Score: 0.002
  89. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res. 1985 Jan; 45(1):293-304.
    View in: PubMed
    Score: 0.002
  90. Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. Lab Invest. 1984 Nov; 51(5):495-503.
    View in: PubMed
    Score: 0.002
  91. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004 Dec; 18(12):2854-65.
    View in: PubMed
    Score: 0.002
  92. An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. Lab Invest. 1984 Apr; 50(4):480-6.
    View in: PubMed
    Score: 0.002
  93. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 1984 Feb 23-29; 307(5953):745-7.
    View in: PubMed
    Score: 0.002
  94. Immunochemical studies of estrogen receptors. J Steroid Biochem. 1984 Jan; 20(1):51-6.
    View in: PubMed
    Score: 0.002
  95. Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. Breast Cancer Res Treat. 2003 Mar; 78(1):127-31.
    View in: PubMed
    Score: 0.002
  96. Monoclonal antibodies as probes for estrogen receptor detection and characterization. J Steroid Biochem. 1982 Mar; 16(3):353-9.
    View in: PubMed
    Score: 0.002
  97. A novel mitogen-activated protein kinase is responsive to Raf and mediates growth factor specificity. Mol Cell Biol. 2001 Mar; 21(6):2235-47.
    View in: PubMed
    Score: 0.002
  98. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000 Nov 30; 74(5):311-7.
    View in: PubMed
    Score: 0.002
  99. Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci U S A. 1980 Sep; 77(9):5115-9.
    View in: PubMed
    Score: 0.002
  100. Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol Endocrinol. 1999 Jun; 13(6):897-909.
    View in: PubMed
    Score: 0.001
  101. Estrogen response elements function as allosteric modulators of estrogen receptor conformation. Mol Cell Biol. 1998 Apr; 18(4):1927-34.
    View in: PubMed
    Score: 0.001
  102. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16; 389(6652):753-8.
    View in: PubMed
    Score: 0.001
  103. Isolation and cloning of human peroxisome proliferator activated receptor gamma cDNA. Adv Exp Med Biol. 1997; 400A:253-60.
    View in: PubMed
    Score: 0.001
  104. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation. 1996 Sep 15; 94(6):1402-7.
    View in: PubMed
    Score: 0.001
  105. Estrogen receptor affinity and location of consensus and imperfect estrogen response elements influence transcription activation of simplified promoters. Mol Endocrinol. 1996 Jun; 10(6):694-704.
    View in: PubMed
    Score: 0.001
  106. Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry. 1995 Oct 03; 34(39):12605-15.
    View in: PubMed
    Score: 0.001
  107. Estrogen receptor determination in endometrial carcinoma: ligand binding assay versus enzyme immunoassay. Anticancer Res. 1995 Mar-Apr; 15(2):649-54.
    View in: PubMed
    Score: 0.001
  108. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995; 4(4-5):281-99.
    View in: PubMed
    Score: 0.001
  109. Human estrogen receptor bound to an estrogen response element bends DNA. Mol Endocrinol. 1993 Mar; 7(3):331-40.
    View in: PubMed
    Score: 0.001
  110. The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202.
    View in: PubMed
    Score: 0.001
  111. The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol. 1992 Feb; 6(2):157-67.
    View in: PubMed
    Score: 0.001
  112. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6.
    View in: PubMed
    Score: 0.001
  113. Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays. Eur J Cancer. 1992; 28(2-3):322-6.
    View in: PubMed
    Score: 0.001
  114. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst. 1991 Aug 21; 83(16):1157-60.
    View in: PubMed
    Score: 0.001
  115. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991 Jan 01; 51(1):239-44.
    View in: PubMed
    Score: 0.001
  116. Immunohistochemical analysis of estrogen and progesterone receptors in benign breast diseases. Zentralbl Pathol. 1991; 137(3):227-32.
    View in: PubMed
    Score: 0.001
  117. Estrogen receptor gene methylation in human breast tumors. Cancer Res. 1990 Jul 01; 50(13):3974-8.
    View in: PubMed
    Score: 0.001
  118. The use of fine needle aspirates in the evaluation of progesterone receptor content in breast cancer. Acta Cytol. 1990 Jan-Feb; 34(1):27-30.
    View in: PubMed
    Score: 0.001
  119. Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J Biol Chem. 1989 Oct 15; 264(29):17476-85.
    View in: PubMed
    Score: 0.001
  120. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res. 1989 Sep 15; 49(18):5176-9.
    View in: PubMed
    Score: 0.001
  121. Immunocytochemical assay of progesterone receptors in paraffin-embedded specimens of endometrial carcinoma and hyperplasia: a preliminary evaluation. Mod Pathol. 1989 Sep; 2(5):449-55.
    View in: PubMed
    Score: 0.001
  122. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989 Feb 15; 49(4):1052-6.
    View in: PubMed
    Score: 0.001
  123. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol. 1989 Feb; 3(2):295-304.
    View in: PubMed
    Score: 0.001
  124. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989 Jan 01; 49(1):145-8.
    View in: PubMed
    Score: 0.001
  125. Progesterone receptors in the human heart and great vessels. Lab Invest. 1988 Sep; 59(3):353-6.
    View in: PubMed
    Score: 0.001
  126. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab. 1988 Aug; 67(2):334-40.
    View in: PubMed
    Score: 0.001
  127. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988 Jul 01; 241(4861):81-4.
    View in: PubMed
    Score: 0.001
  128. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology. 1988 Mar; 122(3):935-44.
    View in: PubMed
    Score: 0.001
  129. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol. 1988 Mar; 2(3):263-71.
    View in: PubMed
    Score: 0.001
  130. Immunostaining of estrogen receptor in paraffin sections of breast carcinomas using monoclonal antibody D75P3 gamma: effects of fixation. Am J Surg Pathol. 1987 Dec; 11(12):943-50.
    View in: PubMed
    Score: 0.001
  131. Cellular progesterone receptor phosphorylation in response to ligands activating protein kinases. Biochem Biophys Res Commun. 1987 Aug 14; 146(3):1357-65.
    View in: PubMed
    Score: 0.001
  132. The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proc Natl Acad Sci U S A. 1987 May; 84(9):2877-81.
    View in: PubMed
    Score: 0.001
  133. Structural organization and regulation of the chicken estrogen receptor. Mol Endocrinol. 1987 Jan; 1(1):25-35.
    View in: PubMed
    Score: 0.001
  134. Estrogen receptor localization in formalin-fixed, paraffin-embedded endometrium and endometriotic tissues. Int J Gynecol Pathol. 1987; 6(2):140-51.
    View in: PubMed
    Score: 0.001
  135. Molecular cloning of the chicken progesterone receptor. Science. 1986 Aug 15; 233(4765):767-70.
    View in: PubMed
    Score: 0.001
  136. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem. 1986 Jan; 24(1):77-83.
    View in: PubMed
    Score: 0.001
  137. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A. 1985 Dec; 82(23):7889-93.
    View in: PubMed
    Score: 0.001
  138. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology. 1985 Oct; 117(4):1409-17.
    View in: PubMed
    Score: 0.001
  139. Characterization of the subunit nature of nuclear estrogen receptors by chemical cross-linking and dense amino acid labeling. Endocrinology. 1985 Aug; 117(2):515-22.
    View in: PubMed
    Score: 0.001
  140. Relation of estrogen receptor expression to clonal growth and antiestrogen effects on human breast cancer cells. Cancer Res. 1985 Jun; 45(6):2720-4.
    View in: PubMed
    Score: 0.001
  141. A novel nuclear form of estradiol receptor in MCF-7 human breast cancer cells. Science. 1984 Sep 14; 225(4667):1162-5.
    View in: PubMed
    Score: 0.001
  142. Monoclonal and anti-idiotypic antibodies as probes for receptor structure and function. Fed Proc. 1984 Jul; 43(10):2532-9.
    View in: PubMed
    Score: 0.001
  143. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res. 1984 Mar; 44(3):1012-8.
    View in: PubMed
    Score: 0.001
  144. Estrogen receptors, antibodies and hormone dependent cancer. Prog Clin Biol Res. 1984; 142:1-21.
    View in: PubMed
    Score: 0.000
  145. Estrogen receptor transformation in MCF-7 breast cancer cells: characterization by immunochemical and sedimentation analyses. Endocrinology. 1984 Jan; 114(1):296-8.
    View in: PubMed
    Score: 0.000
  146. Estrogen receptors in human prostate: evidence for multiple binding sites. J Clin Endocrinol Metab. 1983 Jul; 57(1):166-76.
    View in: PubMed
    Score: 0.000
  147. Interaction of [3H] estradiol - and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Res Treat. 1983; 3(3):267-77.
    View in: PubMed
    Score: 0.000
  148. Receptors reconsidered: a 20-year perspective. Recent Prog Horm Res. 1982; 38:1-40.
    View in: PubMed
    Score: 0.000
  149. Squamous-cell carcinoma of the floor of the mouth. Oral Surg Oral Med Oral Pathol. 1978 Apr; 45(4):568-79.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.